Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares of 112.42M shares rose 45.8% year over year, behind the +48.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 49.0% from the prior quarter. Over 3 fiscal years it compounded at +78.9% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +45.8% toward the trailing-twelve-month pace of +48.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 81.84M USD
- Year-over-year change
- +68.6%
- 4-year CAGR
- +53.3%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.84M | +68.6% |
| FY2024 | 2024-12-31 | 48.54M | +97.2% |
| FY2023 | 2023-12-31 | 24.62M | +72.3% |
| FY2022 | 2022-12-31 | 14.29M | -3.6% |
| FY2021 | 2021-12-31 | 14.82M | — |
Weighted Avg Shares vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 weighted avg shares of 85.54M shares is the 4th highest of the 11 companies compared; the peer median is 59.01M shares.
- Its year-over-year change of +48.0% is the highest of 11, against a peer median of +7.6%.
- Over three fiscal years its annual growth of +78.9% compares with a peer median of +12.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Mar 2026 | 167.44M | +37.1% | +15.3% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 85.54M | +48.0% | +78.9% | |
| LTM Mar 2026 | 80.03M | -5.4% | -0.7% | |
| LTM Mar 2026 | 59.11M | +1.3% | +1.4% | |
| LTM Mar 2026 | 58.91M | +1.6% | +15.2% | |
| LTM Mar 2026 | 54.09M | +20.9% | +88.9% | |
| LTM Mar 2026 | 50.31M | +2.7% | +3.8% | |
| LTM Mar 2026 | 48.09M | +39.5% | +60.3% | |
| LTM Mar 2026 | 41.5M | +5.9% | +9.8% | |
| Peer median (excluding ELDN) | 59.01M | +7.6% | +12.5% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.